A double-blind, placebo-controlled study of vortioxetine in the treatment of binge-eating disorder.

ABSTRACT:

Background

Binge-eating disorder (BED) is associated with impaired quality of life and has a number of untoward public health associations. There are few established pharmacological treatments for BED, and available options are not suitable for all individuals. Vortioxetine is a recently developed pharmacological agent with effects on the serotonergic but also other neurochemical systems, which has yet to be evaluated in this context.

Method

Eighty adults with BED were recruited for a double-blind, placebo-controlled study. Participants received 12-week treatment with vortioxetine (10 mg/day for 1 week, then increasing to 20 mg/day) or placebo in a parallel design. The primary efficacy outcome measures were binge-eating frequency and weight. Safety data were collected. Effec

SUBMITTER: Grant JE 

PROVIDER: S-EPMC7102903 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature